Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Case Comprehensive Cancer Center
• Treatments: Aminolevulinic Acid

Criteria

Inclusion Criteria:

• Adults scheduled to undergo Mohs surgery within the Dermatologic Surgery unit of the Department of Dermatology, Cleveland Clinic

• Must have at least two BCC tumors eligible for removal by Mohs surgery

• Men and women of any ethnic group are eligible

• Must provide informed consent to participate

Exclusion Criteria:

• Pregnant or breastfeeding

• Currently being treated for other cancers with medical or radiation therapy

• Known hypersensitivity to 5-aminolevulinic acid (ALA)

• History of a photosensitivity disease, e.g.,porphyria cutanea tarda